Source: https://ir.avalon-globocare.com/quarterly-reports/content/0001213900-19-008592/f10q0319_avalonglobocare.htm?TB_iframe=true&height=auto&width=auto&preload=false
Timestamp: 2019-08-18 13:41:57
Document Index: 635517240

Matched Legal Cases: ['arty 1', 'arty 100', 'arty 1', 'arty 14', 'arty 13', 'arty 1', 'arty 14']

4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728
(732) 780-4400
Common Stock, $0.0001 par value per share AVCO The NASDAQ Capital Market
Class Outstanding May 14, 2019
Common Stock, $0.0001 par value per share 75,655,639 shares
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2019 and 2018 2
Unaudited Condensed Consolidated Statement of Changes in Equity for the Three Months Ended March 31, 2019 3
Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2019 and 2018 4
Item 3 Quantitative and Qualitative Disclosures About Market Risk 40
Cash $ 1,769,291 $ 2,252,287
Accounts receivable, net of allowance for doubtful accounts 11,292 9,739
Tenants receivable, net of allowance for doubtful accounts 48,057 42,484
Security deposit 127,968 127,263
Inventory 17,121 12,994
Prepaid expenses - related parties - 34,190
Prepaid expenses and other current assets 949,673 1,146,475
Total Current Assets 2,923,402 3,625,432
Property and equipment, net 398,697 249,555
Investment in real estate, net 7,851,262 7,879,885
Intangible assets, net 1,173,796 1,255,689
Equity method investment 381,899 385,162
Total Non-current Assets 9,805,654 9,770,291
Total Assets $ 12,729,056 $ 13,395,723
Accounts payable $ 41,123 $ 6,695
Advance from customer - related party - 14,829
Accrued liabilities and other payables 1,291,078 859,350
Accrued liabilities and other payables - related parties 34,378 -
Deferred rental income 3,012 14,136
Loan payable 1,000,000 -
Interest payable 100,000 75,342
Interest payable - related party 1,944 -
VAT and other taxes payable 25,638 4,668
Tenants’ security deposit 66,580 66,700
Due to related party 100,000 100,000
Total Current Liabilities 2,663,753 1,141,720
Loan payable - noncurrent portion - 1,000,000
Note payable - related party 1,000,000 -
Total Non-current Liabilities 1,000,000 1,000,000
Total Liabilities 3,663,753 2,141,720
Commitments and Contingencies - (Note 18)
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2019 and December 31, 2018 - -
Common stock, $0.0001 par value; 490,000,000 shares authorized; 74,340,539 shares issued and 73,820,539 shares outstanding at March 31, 2019; 73,830,751 shares issued and 73,310,751 shares outstanding at December 31, 2018 7,434 7,383
Additional paid-in capital 26,426,074 24,153,378
Less: common stock held in treasury, at cost; 520,000 shares at March 31, 2019 and December 31, 2018 (522,500 ) (522,500 )
Accumulated deficit (15,697,592 ) (11,291,776 )
Accumulated other comprehensive loss - foreign currency translation adjustment (192,180 ) (236,860 )
Total Avalon GloboCare Corp. stockholders’ equity 10,027,814 12,116,203
Non-controlling interest (962,511 ) (862,200 )
Total Equity 9,065,303 11,254,003
Total Liabilities and Equity $ 12,729,056 $ 13,395,723
Real property rental $ 266,626 $ 296,623
Medical related consulting services - related party 14,260 -
Development services and sales of developed products 3,278 11,290
Total Revenues 284,164 307,913
Real property operating expenses 230,759 210,274
Medical related consulting services - related party 13,091 -
Development services and sales of developed products 30,307 16,520
Total Costs and Expenses 274,157 226,794
REAL PROPERTY OPERATING INCOME 35,867 86,349
GROSS PROFIT FROM MEDICAL RELATED CONSULTING SERVICES 1,169 -
GROSS LOSS FROM DEVELOPMENT SERVICES AND SALES OF DEVELOPED PRODUCTS (27,029 ) (5,230 )
Advertising expenses 244,600 -
Compensation and related benefits 2,100,155 538,814
Professional fees 1,468,226 571,772
Research and development expenses 152,460 -
Other general and administrative 509,879 285,252
Total Other Operating Expenses 4,475,320 1,395,838
LOSS FROM OPERATIONS (4,465,313 ) (1,314,719 )
Interest income 768 408
Interest expense (25,697 ) (236,986 )
Interest expense - related party (1,944 ) -
Loss from equity-method investment (12,743 ) -
Other income - 328
Total Other Expense, net (39,616 ) (236,250 )
LOSS BEFORE INCOME TAXES (4,504,929 ) (1,550,969 )
NET LOSS $ (4,504,929 ) $ (1,550,969 )
LESS: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST (99,113 ) (69,390 )
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS $ (4,405,816 ) $ (1,481,579 )
NET LOSS (4,504,929 ) (1,550,969 )
Unrealized foreign currency translation gain 43,482 52,838
COMPREHENSIVE LOSS $ (4,461,447 ) $ (1,498,131 )
LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST (100,311 ) (69,230 )
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS $ (4,361,136 ) $ (1,428,901 )
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:
Basic and diluted $ (0.06 ) $ (0.02 )
Basic and diluted 73,690,461 69,781,733
Avalon GloboCare Corp. Stockholders’ Equity
Preferred Stock Common Stock Additional Treasury Stock
Number of Number of Paid-in Number of Accumulated Statutory
Shares Amount Shares Amount Capital Shares Amount Deficit Reserve Loss Interest Equity
Balance, December 31, 2017 - $ - 70,278,622 $ 7,028 $ 11,490,285 - $ - $ (3,517,654 ) $ 6,578 $ (91,994 ) $ (585,394 ) $ 7,308,849
Treasury stock purchase - - - - - (520,000 ) (522,500 ) - - - - (522,500 )
Stock-based compensation and service fees - - - - 526,348 - - - - - - 526,348
Foreign currency translation adjustment - - - - - - - - - 52,678 160 52,838
Net loss for the three months ended March 31, 2018 - - - - - - - (1,481,579 ) - - (69,390 ) (1,550,969 )
Balance, March 31, 2018 - $ - 70,278,622 $ 7,028 $ 12,016,633 (520,000 ) $ (522,500 ) $ (4,999,233 ) $ 6,578 $ (39,316 ) $ (654,624 ) $ 5,814,566
Balance, December 31, 2018 - $ - 73,830,751 $ 7,383 $ 24,153,378 (520,000 ) $ (522,500 ) $ (11,291,776 ) $ 6,578 $ (236,860 ) $ (862,200 ) $ 11,254,003
Issuance of common stock upon cashless exercise of stock options - - 350,856 35 (35 ) - - - - - - -
Issuance of common stock upon exercise of warrants - - 158,932 16 (16 ) - - - - - - -
Stock-based compensation - - - - 2,272,747 - - - - - - 2,272,747
Foreign currency translation adjustment - - - - - - - - - 44,680 (1,198 ) 43,482
Net loss for the three months ended March 31, 2019 - - - - - - - (4,405,816 ) - - (99,113 ) (4,504,929 )
Balance, March 31, 2019 - $ - 74,340,539 $ 7,434 $ 26,426,074 (520,000 ) $ (522,500 ) $ (15,697,592 ) $ 6,578 $ (192,180 ) $ (962,511 ) $ 9,065,303
Depreciation and amortization 139,131 123,379
Stock-based compensation expense 2,272,747 526,348
Loss on equity method investment 12,743 -
Accounts receivable (1,305 ) 3,469
Tenants receivable (5,573 ) 479
Inventory (3,947 ) (7,372 )
Prepaid expenses - related parties 34,814 -
Prepaid expenses and other current assets 197,829 75,693
Security deposit (37 ) 5,284
Accounts payable 34,080 (30 )
Advance from customer - related party (15,115 ) -
Accrued liabilities and other payables 346,694 178,136
Accrued liabilities and other payables - related parties 34,326 (14,498 )
Deferred rental income (11,124 ) (5,515 )
Interest payable 24,658 236,986
VAT and other taxes payable 20,873 31,264
Tenants’ security deposit (120 ) (18,888 )
NET CASH USED IN OPERATING ACTIVITIES (1,422,311 ) (416,234 )
Purchase of property and equipment (76,033 ) (7,852 )
Improvement of commercial real estate (11,338 ) -
NET CASH USED IN INVESTING ACTIVITIES (87,371 ) (7,852 )
Proceeds received from note payable - related party 1,000,000 -
Repurchase of common stock - (522,500 )
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 1,000,000 (522,500 )
EFFECT OF EXCHANGE RATE ON CASH 26,686 45,209
NET DECREASE IN CASH (482,996 ) (901,377 )
CASH - beginning of period 2,252,287 3,027,033
CASH - end of period $ 1,769,291 $ 2,125,656
Interest $ 1,039 $ -
Property and equipment acquired on credit as payable $ 84,348 $ -
Acquisition of equipment by decreasing prepayment for long-term assets $ - $ 110,103
Avalon GloboCare Corp. (f/k/a Global Technologies Corp.) (the “Company” or “AVCO”) is a Delaware corporation. The Company was incorporated under the laws of the State of Delaware on July 28, 2014. On October 18, 2016, the Company changed its name to Avalon GloboCare Corp. and completed a reverse split its shares of common stock at a ratio of 1:4. On October 19, 2016, the Company entered into and closed a Share Exchange Agreement with the shareholders of Avalon Healthcare System, Inc., a Delaware corporation (“AHS”), each of which are accredited investors (“AHS Shareholders”) pursuant to which we acquired 100% of the outstanding securities of AHS in exchange for 50,000,000 shares of our common stock (the “AHS Acquisition”). AHS was incorporated on May 18, 2015 under the laws of the State of Delaware. As a result of such acquisition, the Company’s operations now are focused on integrating and managing global healthcare services and resources, as well as empowering high-impact biomedical innovations and technologies to accelerate their clinical applications. We are dedicated to advancing cell-based technologies and therapeutics, as well as empowering high-impact biomedical innovations to accelerate their clinical applications. Our ecosystem covers the areas of exosome technology (including liquid biopsy and regenerative therapeutics) and cellular immunotherapy. We plan to integrate technologies and services through joint venture and subsidiary structures that bring shareholder value both in the short term, through operational entities and long term, through biomedical innovation development, such as our recent joint venture for the advancement of exosome isolation systems and related products. AHS owns 100% of the capital stock of Avalon (Shanghai) Healthcare Technology Co., Ltd. (“Avalon Shanghai”), which is a wholly foreign-owned enterprise organized under the laws of the People’s Republic of China (“PRC”). Avalon Shanghai was incorporated on April 29, 2016 and is engaged in medical related consulting services for customers.
On January 23, 2017, the Company incorporated Avalon (BVI) Ltd., a British Virgin Island company. There was no activity for the subsidiary since its incorporation through March 31, 2019. Avalon (BVI) Ltd. is dormant and is in process of being dissolved.
On February 7, 2017, the Company formed Avalon RT 9 Properties, LLC (“Avalon RT 9”), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold, NJ 07728. This property was purchased to serve as the Company’s world-wide headquarters for all corporate administration and operation. In addition, the property generates rental income. Avalon RT 9 owns this office building. Currently, Avalon RT 9’s business consists of the ownership and operation of the income-producing real estate property in New Jersey.
On July 31, 2017, the Company formed GenExosome Technologies Inc. (“GenExosome”) in Nevada.
On October 25, 2017, GenExosome and the Company entered into a Securities Purchase Agreement pursuant to which the Company acquired 600 shares of GenExosome in consideration of $1,326,087 in cash and 500,000 shares of common stock of the Company.
On October 25, 2017, GenExosome entered into and closed an Asset Purchase Agreement with Yu Zhou, MD, PhD, pursuant to which the Company acquired all assets, including all intellectual property, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies including, but not limited to, patent application number CN 2016 1 0675107.5 (application of an Exosomal MicroRNA in plasma as biomaker to diagnosis liver cancer), patent application number CN 2016 1 0675110.7 (clinical application of circulating exosome carried miRNA-33b in the diagnosis of liver cancer), patent application number CN 2017 1 0330847.X (saliva exosome based methods and composition for the diagnosis, staging and prognosis of oral cancer) and patent application number CN 2017 1 0330835.7 (a novel exosome-based therapeutics against proliferative oral diseases). In consideration of the assets, GenExosome agreed to pay Dr. Zhou $876,087 in cash, transfer 500,000 shares of common stock of the Company to Dr. Zhou and issue Dr. Zhou 400 shares of common stock of GenExosome.
As a result of the above transactions, effective October 25, 2017, the Company holds 60% of GenExosome and Dr. Zhou holds 40% of GenExosome. GenExosome is engaged in developing proprietary diagnostic and therapeutic products leveraging its exosome technology and marketing and distributing its proprietary Exosome Isolation Systems.
On October 25, 2017, GenExosome entered into and closed a Stock Purchase Agreement with Beijing Jieteng (GenExosome) Biotech Co. Ltd., a corporation incorporated in the People’s Republic of China on August 7, 2015 (“Beijing GenExosome”) and Dr. Zhou, the sole shareholder of Beijing GenExosome, pursuant to which GenExosome acquired all of the issued and outstanding securities of Beijing GenExosome in consideration of a cash payment in the amount of $450,000.
NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS (continued)
Beijing GenExosome is engaged in the development of exosome technology to improve diagnosis and management of diseases. Exosomes are tiny, subcellular, membrane-bound vesicles in diameter of 30-150 nm that are released by almost all cell types and that can carry membrane and cellular proteins, as well as genetic materials that are representative of the cell of origin. Profiling various bio-molecules in exosomes may serve as useful biomarkers for a wide variety of diseases. Beijing GenExosome’s research kits are designed to be used by researchers for biomarker discovery and clinical diagnostic development, and the advancement of targeted therapies. Currently, research kits and service are available to isolate exosomes or extract exosomal RNA/protein from serum/plasma, urine and saliva samples. Beijing GenExosome is seeking to decode proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive “liquid biopsies”. Its mission is focused toward diagnostic advancements in the fields of oncology, infectious diseases and fibrotic diseases, and discovery of disease-specific exosomes to provide disease origin insight necessary to enable personalized clinical management.
On July 18, 2018, the Company formed a wholly owned subsidiary, Avactis Biosciences Inc., a Nevada corporation, which will be focused on accelerating commercial activities related to cellular therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others. The subsidiary is designed to integrate and optimize our global scientific and clinical resources to further advance the use of cellular therapies to treat certain cancers. There was no activity for the subsidiary since its incorporation through March 31, 2019.
Details of the Company’s subsidiaries which are included in these consolidated financial statements as of March 31, 2019 are as follows:
Avalon Healthcare System, Inc.
(“AHS”) Delaware
May 18, 2015 100% held by AVCO Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (“USA”)
Avalon (BVI) Ltd.
(“Avalon BVI”) British Virgin Island
January 23, 2017 100% held by AVCO Dormant,
is in process of being dissolved
Avalon RT 9 Properties LLC
(“Avalon RT 9”) New Jersey
February 7, 2017 100% held by AVCO Owns and operates an income-producing real property and holds and manages the corporate headquarters
Avalon (Shanghai) Healthcare Technology Co., Ltd.
(“Avalon Shanghai”) PRC
April 29, 2016 100% held by AHS Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in China
(“GenExosome”) Nevada
July 31, 2017 60% held by AVCO Develops proprietary diagnostic and therapeutic products leveraging exosome technology and markets and distributes proprietary Exosome Isolation Systems in USA
Beijing Jieteng (GenExosome) Biotech Co., Ltd.
(“Beijing GenExosome”) PRC
August 7, 2015 100% held by GenExosome Provides development services for hospitals and other customers and sells developed items to hospitals and other customers in China
Avactis Biosciences Inc.
(“Avactis”) Nevada
July 18, 2018 100% held by AVCO Integrate and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers
Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on March 26, 2019.
The preparation of the unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates during the three months ended March 31, 2019 and 2018 include the allowance for doubtful accounts, reserve for obsolete inventory, the useful life of property and equipment and investment in real estate and intangible assets, assumptions used in assessing impairment of long-term assets, valuation of deferred tax assets and the associated valuation allowances, and valuation of stock-based compensation.
● Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
● Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
● Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash, accounts receivable, tenants receivable, security deposit, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities and other payables, accrued liabilities and other payables – related parties, deferred rental income, loan payable, interest payable, interest payable – related party, Value Added Tax (“VAT”) and other taxes payable, tenants’ security deposit, and due to related party, approximate their fair market value based on the short-term maturity of these instruments.
At March 31, 2019 and December 31, 2018, intangible assets were measured at fair value on a nonrecurring basis as shown in the following tables.
Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs
March 31, 2019 Impairment
Patents and other technologies $ - $ - $ 1,173,796 $ 1,173,796 $ -
(Level 3) Balance at December 31,
2018 Impairment
Patents and other technologies $ - $ - $ 1,255,689 $ 1,255,689 $ -
Cash consists of cash on hand and cash in banks. The Company maintains cash with various financial institutions in the PRC and United States. At March 31, 2019 and December 31, 2018, cash balances in PRC are $814,166 and $1,216,485, respectively, are uninsured. At March 31, 2019 and December 31, 2018, cash balances in United States are $955,125 and $1,035,802, respectively. The Company has not experienced any losses in bank accounts and believes it is not exposed to any risks on its cash in bank accounts.
Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash, trade accounts receivable and tenants receivable. A portion of the Company’s cash is maintained with state-owned banks within the PRC, and none of these deposits are covered by insurance. The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts. A portion of the Company’s sales are credit sales which is to the customer whose ability to pay is dependent upon the industry economics prevailing in these areas; however, concentrations of credit risk with respect to trade accounts receivable and tenants receivable is limited due to generally short payment terms. The Company also performs ongoing credit evaluations of its customers to help further reduce credit risk.
Concentrations of Credit Risk (continued)
At March 31, 2019 and December 31, 2018, the Company’s cash balances by geographic area were as follows:
Country: March 31, 2019 December 31, 2018
United States $ 955,125 54.0 % $ 1,035,802 46.0 %
China 814,166 46.0 % 1,216,485 54.0 %
Total cash $ 1,769,291 100.0 % $ 2,252,287 100.0 %
Accounts receivable are presented net of an allowance for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses. The Company reviews the accounts receivable on a periodic basis and makes general and specific allowances when there is doubt as to the collectability of individual balances. In evaluating the collectability of individual receivable balances, the Company considers many factors, including the age of the balance, a customer’s historical payment history, its current credit-worthiness and current economic trends. Accounts are written off after exhaustive efforts at collection.
Management believes that the accounts receivable are fully collectable. Therefore, no allowance for doubtful accounts is deemed to be required on its accounts receivable at March 31, 2019 and December 31, 2018. The Company historically has not experienced uncollectible accounts from customers granted with credit sales.
Tenants receivable are presented net of an allowance for doubtful accounts. Tenants receivable balance consist of base rents, tenant reimbursements and receivables arising from straight-lining of rents primarily represent amounts accrued and unpaid from tenants in accordance with the terms of the respective leases, subject to the Company’s revenue recognition policy. An allowance for the uncollectible portion of tenant receivable is determined based upon an analysis of the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in Freehold, New Jersey in which the property is located.
Management believes that the tenants receivable are fully collectable. Therefore, no allowance for doubtful accounts is deemed to be required on its tenants receivable at March 31, 2019 and December 31, 2018.
Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. A reserve is established when management determines that certain inventory may not be saleable. If inventory costs exceed expected market value due to obsolescence or quantities in excess of expected demand, the Company will record a write down in inventory for the difference between the cost and the lower of cost or estimated net realizable value. The reserve and write down are recorded based on estimates. The Company did not record any inventory reserve and or write down at March 31, 2019 and December 31, 2018.
Property and equipment are carried at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the period of disposition. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.
Investment in real estate is carried at cost less accumulated depreciation and consists of building and improvement. The Company depreciates real estate building and improvement on a straight-line basis over estimated useful life. Expenditures for ordinary repair and maintenance costs are charged to expense as incurred. Expenditure for improvements, renovations, and replacements of real estate asset is capitalized and depreciated over its estimated useful life if the expenditure qualifies as betterment. Real estate depreciation expense was $39,961 and $31,805 for the three months ended March 31, 2019 and 2018, respectively.
Intangible assets consist of patents and other technologies. Patents and other technologies are being amortized on a straight-line method over the estimated useful life of 5 years.
Investment in Unconsolidated Company – Epicon Biotech Co., Ltd.
The Company uses the equity method of accounting for its investment in, and earning or loss of, company that it does not control but over which it does exert significant influence. The Company considers whether the fair value of its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that recorded value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including historical financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. See Note 9 for discussion of equity method investment.
In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did not record any impairment charge for the three months ended March 31, 2019 and 2018 as there was no impairment indicator noted as of the filing date of this report.
Deferred rental income represents rental income collected but not earned as of the reporting date. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. As of March 31, 2019 and December 31, 2018, deferred rental income totaled $3,012 and $14,136, respectively.
Avalon Shanghai and Beijing GenExosome are subject to a value added tax (“VAT”) for providing medical related consulting services and performing development services and sales of developed products. The amount of VAT liability is determined by applying the applicable tax rates to the invoiced amount of medical related consulting services provided and the invoiced amount of development services provided and sales of developed products (output VAT) less VAT paid on purchases made with the relevant supporting invoices (input VAT). The Company reports revenue net of PRC’s value added tax for all the periods presented in the consolidated statements of operations.
Effective January 1, 2018, the Company began recognizing revenue under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. The impact of adopting the new revenue standard was not material to the Company’s consolidated financial statements and there was no adjustment to beginning accumulated deficit on January 1, 2018. The core principle of this new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:
● Step 1: Identify the contract with the customer
● Step 2: Identify the performance obligations in the contract
● Step 3: Determine the transaction price
● Step 4: Allocate the transaction price to the performance obligations in the contract
● Step 5: Recognize revenue when the company satisfies a performance obligation
In order to identify the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or service that is distinct. A performance obligation meets ASC 606’s definition of a “distinct” good or service (or bundle of goods or services) if both of the following criteria are met:
● The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct).
● The entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract).
If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.
The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.
The transaction price is allocated to each performance obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized when that performance obligation is satisfied, at a point in time or over time as appropriate.
● Rental revenue from leasing commercial property under operating leases with terms of generally three years or more.
● Service fees under consulting agreements with related parties to provide medical related consulting services to its clients. The Company is paid for its services by its clients pursuant to the terms of the written consulting agreements. Each contract calls for a fixed payment.
● Service fees under agreements to perform development services for hospitals and other customers. The Company does not perform contracts that are contingent upon successful results.
● Sales of developed products to hospitals and other customers.
● The Company recognizes rental revenue from its commercial leases on a straight-line basis over the life of the lease including rent holidays, if any. Straight-line rent receivable consists of the difference between the tenants’ rents calculated on a straight-line basis from the date of lease commencement over the remaining terms of the related leases and the tenants’ actual rents due under the lease agreements and is included in tenants receivable in the accompanying consolidated balance sheets. Revenues associated with operating expense recoveries are recognized in the period in which the expenses are incurred.
● The Company recognizes revenue by providing medical related consulting services under written service contracts with its customers. Revenue related to its service offerings is recognized as the services are performed.
● Revenue from development services performed under written contracts is recognized as services are provided.
● Revenue from sales of developed items to hospitals and other customers is recognized when items are shipped to customers and titles are transferred.
The Company does not offer promotional payments, customer coupons, rebates or other cash redemption offers to its customers.
When a lease contains “rent holidays”, the Company records rental expense on a straight-line basis over the term of the lease and the difference between the average rental amount charged to expense and the amount payable under the lease is recorded as prepaid expenses in the consolidated balance sheets. The Company begins recording rent expense on the lease possession date.
Real Property Operating Expenses
Medical Related Consulting Services Costs
Costs of medical related consulting services includes the cost of internal labor and related benefits, travel expenses related to consulting services, subcontractor costs, other related consulting costs, and other overhead costs. Subcontractor costs were costs related to medical related consulting services incurred by our subcontractor, such as medical professional’s compensation and travel costs.
Development Services and Sales of Developed Products Costs
Costs of development services and sales of developed items includes inventory costs, materials and supplies costs, depreciation, internal labor and related benefits, other overhead costs and shipping and handling costs incurred.
Shipping and handling costs are expensed as incurred and are included in cost of sales. For the three months ended March 31, 2019 and 2018, shipping and handling costs amounted to $0 and $25, respectively.
Expenditures for research and product development costs are expensed as incurred. The Company incurred research and development expense in the amount of $152,460 related to the development of proprietary diagnostic and therapeutic products leveraging exosome technology and optimization of Exosome Isolation Systems, and the develop of standardization of clinical-grade exosome bio-production and study of tissue-specific exosomes from various human cell types in the three months ended March 31, 2019. The Company did not incur any research and development costs during the three months ended March 31, 2018.
All costs related to advertising are expensed as incurred. For the three months ended March 31, 2019, advertising costs amounted to $244,600. We did not incur any advertising expense during the three months ended March 31, 2018.
Stock-based compensation is accounted for based on the requirements of the Share-Based Payment topic of Accounting Standards Codification (“ASC”) 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award. The Accounting Standards Codification also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.
Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is recognized over the period of services or the vesting period, whichever is applicable. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company’s compensation expense for unvested options to non-employees is re-measured at each balance sheet date and is being amortized over the vesting period of the options.
The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes”. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. As of March 31, 2019 and December 31, 2018, the Company had no significant uncertain tax positions that qualify for either recognition or disclosure in the financial statements. Tax year that remains subject to examination is the years ended December 31, 2019, 2018 and 2017. The Company recognizes interest and penalties related to significant uncertain income tax positions in other expense. However, no such interest and penalties were recorded as of March 31, 2019 and December 31, 2018.
In December 2017, the United States Government passed new tax legislation that, among other provisions, lowered the corporate tax rate from 35% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income the Company may have, the legislation affects the way the Company can use and carryforward net operating losses previously accumulated and results in a revaluation of deferred tax assets and liabilities recorded on the balance sheet. Given that current deferred tax assets are offset by a full valuation allowance, these changes will have no net impact on the balance sheet. However, when the Company becomes profitable, the Company will receive a reduced benefit from such deferred tax assets.
The reporting currency of the Company is the U.S. dollar. The functional currency of the parent company, AHS, Avalon RT 9, GenExosome, and Avactis, is the U.S. dollar and the functional currency of Avalon Shanghai and Beijing GenExosome, is the Chinese Renminbi (“RMB”). For the subsidiaries whose functional currency is the RMB, result of operations and cash flows are translated at average exchange rates during the period, assets and liabilities are translated at the unified exchange rate at the end of the period, and equity is translated at historical exchange rates. As a result, amounts relating to assets and liabilities reported on the statements of cash flows may not necessarily agree with the changes in the corresponding balances on the balance sheets. Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in determining comprehensive income/loss. Transactions denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.
Asset and liability accounts at March 31, 2019 and December 31, 2018 were translated at 6.7121 RMB to $1.00 and at 6.8785 RMB to $1.00, respectively, which were the exchange rates on the balance sheet dates. Equity accounts were stated at their historical rates. The average translation rates applied to the statements of operations for the three months ended March 31, 2019 and 2018 were 6.7481 RMB and 6.3577 RMB to $1.00, respectively. Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rate.
Comprehensive loss is comprised of net loss and all changes to the statements of equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. For the Company, comprehensive loss for the three months ended March 31, 2019 and 2018 consisted of net loss and unrealized gain from foreign currency translation adjustment.
Basic net loss per share are computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. Potentially dilutive common shares consist of the common shares issuable upon the exercise of common stock options and warrants (using the treasury stock method). Common stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding as they would have had an anti-dilutive impact.
The following table presents a reconciliation of basic and diluted net loss per share:
Net loss available to Avalon GloboCare Corp. common shareholders for basic and diluted net loss per share of common stock $ (4,405,816 ) $ (1,481,579 )
Weighted average common stock outstanding - basic and diluted 73,690,461 69,781,733
Net loss per common share attributable to Avalon GloboCare Corp. common shareholders - basic and diluted $ (0.06 ) $ (0.02 )
The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:
Stock options 5,040,000 2,410,000
Warrants 578,891 -
Potentially dilutive securities 5,618,891 2,410,000
The Company accounts for business acquisition in accordance with ASC No. 805, Business Combinations. The assets acquired and liabilities assumed from the acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The result of operations of the acquired business is included in the Company’s operating result from the date of acquisition.
As of March 31, 2019, Dr. Yu Zhou, director and Co-Chief Executive Officer of GenExosome, who owned 40% of the equity interests of GenExosome, which is not under the Company’s control.
The Company uses “the management approach” in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company’s chief operating decision maker for making operating decisions and assessing performance as the source for determining the Company’s reportable segments. The Company’s chief operating decision maker is the chief executive officer (“CEO”) and president of the Company, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company has determined that it has three reportable business segments: real property operating segment, medical related consulting services segment, and development services and sales of developed products segment. These reportable segments offer different types of services and products, have different types of revenue, and are managed separately as each requires different operating strategies and management expertise.
Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications have no effect on the previously reported financial position, results of operations and cash flows.
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases”, (“ASU 842”) which amended the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 842 is effective for public companies during interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-11, which permits entities to record the right-of-use asset and lease liability on the date of adoption, with no requirement to recast comparative periods.
The Company adopted ASU 842 effective January 1, 2019 using the optional transition method of recognizing a cumulative-effect adjustment to the opening balance of accumulated deficit on January 1, 2019. Therefore, comparative financial information was not adjusted and continues to be reported under the prior lease accounting guidance in ASU 840. The Company elected the transition relief package of practical expedients, and as a result, the Company did not assess 1) whether existing or expired contracts contain embedded leases, 2) lease classification for any existing or expired leases, and 3) whether lease origination costs qualified as initial direct costs. The Company elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less, as well as the land easement practical expedient for maintaining its current accounting policy for existing or expired land easements.
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 with early adoption permitted upon issuance of this ASU. The Company is currently evaluating the potential impact of this new guidance.
At March 31, 2019 and December 31, 2018, inventory consisted of the following:
Raw material $ 17,079 $ 12,953
Finished goods 42 41
17,121 12,994
Less: reserve for obsolete inventory - -
$ 17,121 $ 12,994
At March 31, 2019 and December 31, 2018, prepaid expenses and other current assets consisted of the following:
Prepaid professional fees $ 397,125 $ 607,833
Prepaid research and development service fees 400,000 300,000
Prepaid insurance expense 37,336 72,352
Prepaid listing fee 56,250 -
Prepaid dues and subscriptions 18,750 70,000
Other 40,212 96,290
$ 949,673 $ 1,146,475
At March 31, 2019 and December 31, 2018, property and equipment consisted of the following:
Useful life March 31, 2019 December 31, 2018
Laboratory equipment 5 Years $ 424,368 $ 258,345
Office equipment and furniture 3 – 10 Years 37,089 35,627
Leasehold improvement Shorter of useful life or lease term - 24,446
461,457 318,418
Less: accumulated depreciation (62,760 ) (68,863 )
$ 398,697 $ 249,555
For the three months ended March 31, 2019 and 2018, depreciation expense of property and equipment amounted to $17,277 and $9,681, respectively, of which, $819 and $819 was included in real property operating expenses, $13,175 and $3,768 was included in costs of development services and sales of developed products, and $3,283 and $5,094 was included in other operating expenses, respectively.
NOTE 7 – INVESTMENT IN REAL ESTATE
At March 31, 2019 and December 31, 2018, investment in real estate consisted of the following:
Commercial real property building 39 Years $ 7,708,571 $ 7,708,571
Improvement 12 Years 402,844 391,506
8,111,415 8,100,077
Less: accumulated depreciation (260,153 ) (220,192 )
$ 7,851,262 $ 7,879,885
For the three months ended March 31, 2019 and 2018, depreciation expense of this commercial real property amounted to $39,961 and $31,805, which was included in real property operating expenses.
NOTE 8 – INTANGIBLE ASSETS
At March 31, 2019 and December 31, 2018, intangible assets consisted of the following:
Patents and other technologies 5 Years $ 1,583,260 $ 1,583,260
Less: accumulated amortization (409,464 ) (327,571 )
$ 1,173,796 $ 1,255,689
For the three months ended March 31, 2019 and 2018, amortization expense amounted to $81,893.
Amortization of intangible assets attributable to future periods is as follows:
Year ending March 31: Amortization amount
2020 $ 327,571
2021 327,571
2022 327,571
2023 191,083
$ 1,173,796
NOTE 9 – EQUITY METHOD INVESTMENT
As of March 31, 2019 and December 31, 2018, equity method investment amounted to $381,899 and $385,162, respectively. The investment represents the Company’s subsidiary, Avalon Shanghai’s interest in Epicon Biotech Co., Ltd. (“Epicon”). Epicon was incorporated on August 14, 2018 in PRC. Avalon Shanghai and the other unrelated company, Jiangsu Unicorn Biological Technology Co., Ltd. (“Unicorn”), accounted for 40% and 60% of the total ownership, respectively. Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements.
The Company treats the equity investment in the consolidated financial statements under the equity method. Under the equity method, the investment is initially recorded at cost, adjusted for any excess of the Company’s share of the incorporated-date fair values of the investee’s identifiable net assets over the cost of the investment (if any). Thereafter, the investment is adjusted for the post incorporation change in the Company’s share of the investee’s net assets and any impairment loss relating to the investment. For the three months ended March 31, 2019, the Company’s share of Epicon’s net loss was $12,743, which was included in loss from equity-method investment in the accompanying consolidated statements of operations and comprehensive loss.
Current assets $ 227,165 $ 301,714
Noncurrent assets 64,572 7,015
Current liabilities 7,420 38
Equity 284,317 308,691
Net revenue $ -
Gross profit -
Loss from operation 31,856
Net loss 31,856
NOTE 10 – ACCRUED LIABILITIES AND OTHER PAYABLES
At March 31, 2019 and December 31, 2018, accrued liabilities and other payables consisted of the following:
Accrued payroll liability $ 635,065 $ 529,472
Accrued professional fees 431,947 166,077
Lab equipment purchase payable 84,348 -
Insurance payable 22,690 45,088
Accrued dues and subscriptions 50,000 42,500
Other 67,028 76,213
$ 1,291,078 $ 859,350
NOTE 11 – LOAN PAYABLE
On April 19, 2017, the Company entered into a loan agreement, providing for the issuance of a loan in the principal amount of $2,100,000. The term of the loan is one year. On May 3, 2018, the Company signed an extension agreement with the maturity date of March 31, 2019. On August 3, 2018, the Company signed an extension agreement for the loan with the maturity date of March 31, 2020. The annual interest rate for the loan is 10%. The loan is guaranteed by the Company’s Chairman, Mr. Wenzhao Lu. The Company repaid principal of $600,000, $500,000 and $1,000,000 in November 2017, April 2018 and April 2019, respectively.
As of March 31, 2019, the outstanding principal balance of the loan and related accrued and unpaid interest for the loan was $1,000,000 and $100,000, respectively.
NOTE 12 – VAT AND OTHER TAXES PAYABLE
At March 31, 2019 and December 31, 2018, VAT and other taxes payable consisted of the following:
VAT payable $ - $ 1,108
Other taxes payable 25,638 3,560
$ 25,638 $ 4,668
NOTE 13 – RELATED PARTY TRANSACTIONS
Medical Related Consulting Services Revenue from Related Party
During the three months ended March 31, 2019 and 2018, medical related consulting services revenue from related parties was as follows:
Beijing Daopei (1) $ 14,260 $ -
$ 14,260 $ -
(1) Beijing Daopei is a subsidiary of an entity whose chairman is Wenzhao Lu, the largest shareholder of the Company.
As of March 31, 2019 and December 31, 2018, the Company made prepayment of $0 and $1,897, respectively, to David Jin, its shareholder, chief executive officer, president and board member, for business travel reimbursement, which have been included in prepaid expenses – related parties on the accompanying consolidated balance sheets.
As of March 31, 2019 and December 31, 2018, the Company made prepayment of $0 and $32,293, respectively, to Meng Li, its shareholder and chief operating officer, for business travel reimbursement, which have been included in prepaid expenses – related parties on the accompanying consolidated balance sheets.
Advance from Customer – Related Party
At March 31, 2019 and December 31, 2018, advance from customer – related party amounted to $0 and $14,829, respectively, which represents prepayment received from our related party, Beijing Daopei, for medical related consulting services. When the services are performed, the amount recorded as advance from customer – related party is recognized as revenue.
At March 31, 2019 and December 31, 2018, the Company owed David Jin, its shareholder, chief executive officer, president and board member, of $14,424 and $0, respectively, for travel and other miscellaneous reimbursements, which have been included in accrued liabilities and other payables – related parties on the accompanying consolidated balance sheets.
At March 31, 2019 and December 31, 2018, the Company owed Yu Zhou, co-chief executive officer of GenExosome, of $5,319 and $0, respectively, for travel and other miscellaneous reimbursements, which have been included in accrued liabilities and other payables – related parties on the accompanying consolidated balance sheets.
NOTE 13 – RELATED PARTY TRANSACTIONS (continued)
Accrued Liabilities and Other Payables – Related Parties (continued)
At March 31, 2019 and December 31, 2018, the Company owed Luisa Ingargiola, its chief financial officer, of $7,253 and $0, respectively, for travel and other miscellaneous reimbursements, which have been included in accrued liabilities and other payables – related parties on the accompanying consolidated balance sheets.
At March 31, 2019 and December 31, 2018, the Company owed Epicon of $7,382 and $0, respectively, for expenses paid on behalf of the Company, which have been included in accrued liabilities and other payables – related parties on the accompanying consolidated balance sheets.
In connection with the acquisition discussed elsewhere in this report, the Company acquired Beijing GenExosome in cash payment of $450,000. On October 25, 2017, Dr. Yu Zhou, the former sole shareholder of Beijing GenExosome, was appointed to the board of directors of GenExosome and served as co-chief executive officer of GenExosome. As of March 31, 2019 and December 31, 2018, the unpaid acquisition consideration of $100,000, was payable to Dr. Yu Zhou, co-chief executive officer and board member of GenExosome, and reflected as due to related party on the accompanying consolidated balance sheets.
The Company pays a company, which is controlled by Wenzhao Lu, the Company’s largest shareholder and chairman of the Board of Directors, for the management of its commercial real property located in New Jersey. The property management agreement commenced on May 5, 2017 and expired in March 2019. For the three months ended March 31, 2019 and 2018, the management fee related to the property management agreement amounted to $23,334 and $16,251, respectively.
On March 18, 2019, the Company issued Wenzhao Lu, the Company’s largest shareholder and chairman of the Board of Directors, a Promissory Note in the principal amount of $1,000,000 (“Promissory Note”) in consideration of cash in the amount of $1,000,000. The Promissory Note accrues interest at the rate of 5% per annum and matures March 19, 2022.
As of March 31, 2019, the outstanding principal balance of the note and related accrued and unpaid interest for the note was $1,000,000 and $1,944, respectively.
Office Space from Related Party
Beijing GenExosome uses office space of a related party, free of rent, which is considered immaterial.
NOTE 14 – EQUITY
The Company is authorized to issue 10,000,000 shares of preferred stock and 490,000,000 shares of common shares with a par value of $0.0001 per share.
There are no shares of its preferred stock issued and outstanding as of March 31, 2019 and December 31, 2018.
There are 74,340,539 and 73,830,751 shares of its common stock issued as of March 31, 2019 and December 31, 2018, respectively
There are 73,820,539 and 73,310,751 shares of its common stock outstanding as of March 31, 2019 and December 31, 2018, respectively.
NOTE 14 – EQUITY (continued)
Common Shares Issued for Warrant Exercise
On January 9, 2019, the Company issued 350,856 shares of its common stock upon cashless exercise of warrants to purchase 578,891 shares of common stock.
Common Shares Issued for Option Exercise
On February 27, 2019, the Company issued 158,932 shares of its common stock upon cashless exercise of options to purchase 200,000 shares of common stock.
The following table summarizes the shares of the Company’s common stock issuable upon exercise of options outstanding at March 31, 2019:
Range of Exercise Price Number Outstanding at March 31,
2019 Range of Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable at March 31, 2019 Weighted Average Exercise
$ 0.50 2,000,000 7.87 $ 0.50 1,444,444 $ 0.50
1.49 60,000 3.08 1.49 60,000 1.49
1.00 50,000 3.59 1.00 50,000 1.00
1.00 80,000 1.59 1.00 80,000 1.00
2.50 110,000 3.76 2.50 110,000 2.50
1.00 80,000 2.08 1.00 80,000 1.00
2.30 20,000 4.18 2.30 20,000 2.30
2.30 20,000 4.26 2.30 20,000 2.30
2.80 20,000 4.33 2.80 20,000 2.80
2.80 20,000 4.37 2.80 13,334 2.80
1.00 180,000 2.59 1.00 90,000 1.00
2.75 250,000 4.76 2.75 62,500 2.75
2.00 1,950,000 4.76 2.00 487,500 2.00
$ 0.50–2.80 4,840,000 5.80 $ 1.35 2,537,778 $ 1.07
Stock options granted to employee and director
Employee and director stock option activities for the three months ended March 31, 2019 were as follows:
Outstanding at December 31, 2018 2,280,000 $ 0.69
Granted 2,200,000 2.09
Outstanding at March 31, 2019 4,480,000 $ 1.37
Options exercisable at March 31, 2019 2,274,444 $ 1.07
Options expected to vest 2,205,556 $ 1.69
Stock options granted to employee and director (continued)
The fair values of options granted to employee and director during the three months ended March 31, 2019 and 2018, respectively, were estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:
Dividend rate 0 0
Terms (in years) 5.0 5.0
Volatility 150.61 % 185.28 %
Risk-free interest rate 2.37% - 2.49% 2.25 %
The aggregate fair value of the options granted to employee and director during the three months ended March 31, 2019 was $5,723,438, of which, $1,430,860 for the three months ended March 31, 2019 has been reflected as compensation and related benefits on the accompanying unaudited condensed consolidated statements of operations because the options were fully earned and non-cancellable.
The aggregate fair value of the options granted to employee and director during the three months ended March 31, 2018 was $289,150, of which, $72,287 has been reflected as compensation and related benefits on the accompanying unaudited condensed consolidated statements of operations because the options were fully earned and non-cancellable.
As of March 31, 2019, the aggregate value of nonvested employee and director options was $4,987,024, which will be amortized as stock-based compensation expense as the options are vesting, over the remaining 0.83 years.
The aggregate intrinsic values of the employee and director stock options outstanding and the employee and director stock options exercisable at March 31, 2019 was $18,042,100 and $9,850,501, respectively.
A summary of the status of the Company’s nonvested employee and director stock options granted as of March 31, 2019 and changes during the three months ended March 31, 2019 is presented below:
Number of Options Weighted Average Exercise Price Grant Date Fair Value
Nonvested at December 31, 2018 722,222 $ 0.50 $ 902,779
Granted 2,200,000 2.09 5,723,438
Vested (716,666 ) (1.72 ) (1,639,193 )
Nonvested at March 31, 2019 2,205,556 $ 1.69 $ 4,987,024
Stock Options Granted to Non-employee
Non-employee stock option activities for the three months ended March 31, 2019 were as follows:
Outstanding at December 31, 2018 560,000 $ 1.06
Exercised (200,000 ) 1.00
Outstanding at March 31, 2019 360,000 1.10
Options exercisable at March 31, 2019 263,334 $ 1.09
Options expected to vest 96,666 $ 1.12
Stock Options Granted to Non-employee (continued)
The fair values of these non-employee options vested in three months ended March 31, 2019 and 2018, and nonvested non-employee options as of March 31, 2019 and 2018, respectively, were estimated using the Black-Scholes option-pricing model with the following assumptions:
Terms (in years) 2.59 – 4.50 3.0
Volatility 150.38% – 154.33 % 183.23% - 188.29 %
Risk-free interest rate 2.21% - 2.53 % 2.29% - 2.37 %
Stock-based compensation expense associated with stock options granted to non-employee is recognized as the stock options vest. The stock-based compensation expense related to non-employee will fluctuate as the fair value of the Company’s common stock fluctuates. Stock-based compensation expense associated with stock options granted to non-employee amounted to $633,554 and $210,737 for the three months ended March 31, 2019 and 2018, respectively.
As of March 31, 2019, the aggregate value of vested and nonvested non-employee options was $177,507, which will be amortized as stock-based compensation expense over the remaining 0.38 years.
The aggregate intrinsic values of the non-employee stock options outstanding and the non-employee stock options exercisable at March 31, 2019 was $1,548,000 and $1,134,668, respectively.
A summary of the status of the Company’s nonvested non-employee stock options granted as of March 31, 2019 and changes during the three months ended March 31, 2019 is presented below:
Number of Options Weighted Average Exercise Price Fair Value at
Nonvested at December 31, 2018 193,333 $ 1.12
Vested (96,667 ) (1.12 )
Nonvested at March 31, 2019 96,666 $ 1.12 $ 177,507
Stock warrants activities during the three months ended March 31, 2019 were as follows:
Number of Warrants Weighted Average Exercise Price
Outstanding at December 31, 2018 578,891 $ 1.28
Exercised (578,891 ) (1.28 )
Outstanding and exercisable at March 31, 2019 - $ -
NOTE 15 - STATUTORY RESERVE
Avalon Shanghai and Beijing GenExosome operate in the PRC, are required to reserve 10% of their net profit after income tax, as determined in accordance with the PRC accounting rules and regulations. Appropriation to the statutory reserve by the Company is based on profit arrived at under PRC accounting standards for business enterprises for each year.
The profit arrived at must be set off against any accumulated losses sustained by the Company in prior years, before allocation is made to the statutory reserve. Appropriation to the statutory reserve must be made before distribution of dividends to shareholders. The appropriation is required until the statutory reserve reaches 50% of the registered capital. This statutory reserve is not distributable in the form of cash dividends. The Company did not make any appropriation to statutory reserve for Avalon Shanghai and Beijing GenExosome during the three months ended March 31, 2019 as they incurred net losses in the period.
NOTE 16 – NONCONTROLLING INTEREST
As of March 31, 2019, Dr. Yu Zhou, director and Co-Chief Executive Officer of GenExsome, who owned 40% of the equity interests of GenExosome, which is not under the Company’s control. The following is a summary of noncontrolling interest activities in the three months ended March 31, 2019.
Noncontrolling interest at December 31, 2018 $ (862,200 )
Net loss attributable to noncontrolling interest (99,113 )
Foreign currency translation adjustment attributable to noncontrolling interest (1,198 )
Noncontrolling interest at March 31, 2019 $ (962,511 )
NOTE 17 – RESTRICTED NET ASSETS
A portion of the Company’s operations are conducted through its PRC subsidiaries, which can only pay dividends out of their retained earnings determined in accordance with the accounting standards and regulations in the PRC and after they have met the PRC requirements for appropriation to statutory reserve. In addition, a portion of the Company’s businesses and assets are denominated in RMB, which is not freely convertible into foreign currencies. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with suppliers’ invoices, shipping documents and signed contracts. These currency exchange control procedures imposed by the PRC government authorities may restrict the ability of the Company’s PRC subsidiaries to transfer their net assets to the Parent Company through loans, advances or cash dividends.
Schedule I of Article 5-04 of Regulation S-X requires the condensed financial information of the parent company to be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. For purposes of this test, restricted net assets of consolidated subsidiaries shall mean that amount of the registrant’s proportionate share of net assets of its consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company in the form of loans, advances or cash dividends without the consent of a third party.
The Company’s PRC subsidiaries’ net assets as of March 31, 2019 and December 31, 2018 did not exceed 25% of the Company’s consolidated net assets. Accordingly, Parent Company’s condensed financial statements have not been required in accordance with Rule 5-04 and Rule 12-04 of SEC Regulation S-X.
NOTE 18 – COMMITMENTS AND CONTINCENGIES
In March 2019, Beijing GenExosome signed an agreement to lease its office space under operating lease. Pursuant to the signed lease, the annual rent is RMB 7,000 (approximately $1,000). The term of this lease is one year commencing on March 15, 2019 and expires on March 14, 2020. For the three months ended March 31, 2019, rent expense related to the lease amounted to $43.
Year Ending March 31: Amount
2020 $ 999
Total $ 999
On January 19, 2017, Avalon Shanghai entered into a lease for office space in Beijing, China, with a third party (the “Beijing Office Lease”). Pursuant to the Beijing Office Lease, the monthly rent is RMB 50,586 (approximately $7,500) with a required security deposit of RMB 164,764 (approximately $24,500). In addition, Avalon Shanghai needs to pay monthly maintenance fees of RMB 4,336 (approximately $600). The term of the Beijing Office Lease is 26 months commencing on January 1, 2017 and expired on February 28, 2019 with two months of free rent in the months of December 2017 and February 2019. On December 27, 2018, Avalon Shanghai signed an extension for the lease with expiration date of February 29, 2020. For the three months ended March 31, 2019 and 2018, rent expense and maintenance fees related to the Beijing Office Lease amounted to approximately $22,000 and $26,000, respectively.
2020 $ 90,007
Total $ 90,007
On July 18, 2018, the Company entered into a financing agreement, providing for the issuance of a loan in the principal amount of $108,528. The term of the loan is for a period of 10 months from the execution of the agreement. The annual interest rate for the loan is 6.9%. All of financed amount is used to pay for Directors & Officers Insurance premium. At March 31, 2019 and December 31, 2018, the outstanding principal balance of the loan and related unpaid interest was $22,690 and $45,088, respectively, which was included in the accrued liabilities and other payables on the accompanying consolidated balance sheets.
On May 29, 2018, Avalon Shanghai entered into a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. (“Unicorn”), pursuant to which a company named Epicon Biotech Co., Ltd. (“Epicon”) was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai. Within two years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000 (approximately $1.2 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon, and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.5 million). Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements. As of March 31, 2019, Avalon Shanghai has contributed RMB 3,000,000 (approximately $0.4 million) that was included in equity method investment on the accompanying consolidated balance sheets. Avalon Shanghai intends to use its present working capital together with loans/borrowings/equity raise to fund the project cost.
NOTE 18 – COMMITMENTS AND CONTINCENGIES (continued)
On October 23, 2018, Avactis Biosciences, Inc. (“Avactis”), a wholly-owned subsidiary of the Company, and Arbele Limited (“Arbele”) agreed to the establishment of AVAR BioTherapeutics (China) Co. Ltd. (“AVAR”), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture Agreement (the “AVAR Agreement”), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy in China. Avactis is required to contribute USD $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis’ cash reserves. Within 30 days, Arbele shall make contribution of USD $6.66 million in the form of entering into a License Agreement with AVAR granting AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed upon Avactis and AVAR and services.
● Contributing registered capital of RMB 5,000,000 (approximately $700,000) for working capital purposes as required by local regulation, which is not required to be contributed immediately and will be contributed subject to Avactis’ discretion;
NOTE 19 – SEGMENT INFORMATION
For the three months ended March 31, 2019 and 2018, the Company operated in three reportable business segments - (1) the real property operating segment, (2) the medical related consulting services segment, and (3) the performing development services for hospitals and other customers and sales of developed products to hospitals and other customers segment. The Company’s reportable segments are strategic business units that offer different services and products. They are managed separately based on the fundamental differences in their operations. Information with respect to these reportable business segments for the three months ended March 31, 2019 and 2018 was as follows:
Real property operating $ 266,626 $ 296,623
Medical related consulting services – related party 14,260 -
284,164 307,913
Real property operating 40,781 32,624
Medical related consulting services 2,940 4,006
Development services and sales of developed products 95,410 86,749
139,131 123,379
Real property operating 24,658 236,986
Medical related consulting services - -
Development services and sales of developed products - -
Other (a) 2,983 -
27,641 236,986
Real property operating 98,689 237,700
Medical related consulting services 190,070 100,132
Development services and sales of developed products 247,782 173,474
Other (a) 3,968,388 1,039,663
$ 4,504,929 $ 1,550,969
Identifiable long-lived tangible assets at March 31, 2019 and December 31, 2018 March 31, 2019 December 31, 2018
Real property operating $ 7,868,781 $ 7,898,224
Medical related consulting services 4,066 6,852
Development services and sales of developed products 377,112 224,364
$ 8,249,959 $ 8,129,440
United States $ 7,953,632 $ 7,898,806
China 296,327 230,634
NOTE 20 - CONCENTRATIONS
The following table sets forth information as to each customer that accounted for 10% or more of the Company’s revenues for the three months ended March 31, 2019 and 2018.
Customer Three Months Ended
A 29 % 27 %
B 19 % 18 %
C 15 % 14 %
Two customers, whose outstanding receivable accounted for 10% or more of the Company’s total outstanding accounts receivable and accounts receivable – related party and tenants receivable at March 31, 2019, accounted for 46.6% of the Company’s total outstanding accounts receivable and accounts receivable – related party and tenants receivable at March 31, 2019.
Two customers, whose outstanding receivable accounted for 10% or more of the Company’s total outstanding accounts receivable and accounts receivable – related party and tenants receivable at December 31, 2018, accounted for 56.0% of the Company’s total outstanding accounts receivable and accounts receivable – related party and tenants receivable at December 31, 2018.
No supplier accounted for 10% or more of the Company’s purchase during the three months ended March 31, 2019 and 2018.
Three suppliers, whose outstanding payable accounted for 10% or more of the Company’s total outstanding accounts payable at March 31, 2019, accounted for 91.9% of the Company’s total outstanding accounts payable at March 31, 2019.
One supplier, whose outstanding payable accounted for 10% or more of the Company’s total outstanding accounts payable at December 31, 2018, accounted for 95.5% of the Company’s total outstanding accounts payable at December 31, 2018.
At March 31, 2019 and December 31, 2018, cash balances in the PRC are $814,166 and $1,216,485, respectively, are uninsured. The Company has not experienced any losses in PRC bank accounts and believes it is not exposed to any risks on its cash in PRC bank accounts.
The Company maintains its cash in United States bank and financial institution deposits that at times may exceed federally insured limits. At March 31, 2019 and December 31, 2018, the Company’s cash balances in United States bank accounts had approximately $374,000 and $239,000 in excess of the federally-insured limits, respectively. The Company has not experienced any losses in its United States bank accounts through and as of the date of this report.
NOTE 21 – SUBSEQUENT EVENTS
On April 1, 2019, pursuant to service agreements, the Company issued an aggregate of 120,812 shares of common stock for professional services rendered. These shares were valued at $313,800, the fair market values on the grant dates using the reported closing share prices on the dates of grant, and the Company reduced accrued liabilities of $313,800.
On April 5, 2019, Yue “Charles” Li and Meng Li were appointed to the Board of Directors of the Company to serve as directors of the Company.
NOTE 21 – SUBSEQUENT EVENTS (continued)
Units Sold for Cash
In April 2019, the Company entered into a purchase agreement with several institutional investors for the purchase of 1,714,288 units in a registered direct offering, for gross proceeds of approximately $6 million before placement agent fees and other offering expenses payable by the Company. Each unit was sold at a public offering price of $3.50 and consists of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $3.50. The warrants are exercisable at any time for a five-year period. The Company received net cash proceeds of approximately $5.1 million, net of cash paid for placement agent fees and other offering expenses.
Repayment for Loan Payable
On April 30, 2019, the Company repaid loan payable in the principal amount of $1,000,000.
The following discussion and analysis of our financial condition and results of operations for the three months ended March 31, 2019 and 2018 should be read in conjunction with our unaudited condensed consolidated financial statements and related notes to those unaudited condensed consolidated financial statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under the Risk Factors, Special Note Regarding Forward-Looking Statements and Business sections in our Form 10-K as filed with the Securities and Exchange Commission on March 26, 2019. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.
Unless otherwise indicated, references to the “Company”, “us” or “we” refer to Avalon GloboCare Corp. and its consolidated subsidiaries.
We are dedicated to advancing cell-based technologies and therapeutics, as well as empowering high-impact biomedical innovations to accelerate their clinical applications. Our ecosystem covers the areas of exosome technology (including liquid biopsy and regenerative therapeutics) and cellular immunotherapy. We plan to integrate technologies and services through joint venture and subsidiary structures that bring shareholder value both in the short term, through operational entities and long term, through biomedical innovation development, such as our recent joint venture for the advancement of exosome isolation systems and related products.
In addition, we are engaged in the development of exosome technology to improve the diagnosis and management of diseases. Exosomes are tiny, subcellular, membrane-bound vesicles 30-150 nm in diameter that are released by almost all cell types and can carry membrane and cellular proteins, as well as genetic materials that are representative of the cell of origin. Profiling various bio-molecules in exosomes may serve as useful biomarkers for a wide variety of diseases. Our isolation system is designed to be used by researchers for biomarker discovery, clinical diagnostic development, and advancement of targeted therapies. Currently, isolation systems and service are available to isolate exosomes or extract exosomal RNA/protein from serum/plasma, urine and saliva samples. We are seeking to decode proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive “liquid biopsies”. Our mission is focused on diagnostic advancements in the fields of oncology, infectious diseases and fibrotic diseases, and the discovery of disease-specific exosomes to provide the disease origin insight necessary to enable personalized clinical management.
We currently generate revenue by selling exosome isolation systems in China and the United States through our joint venture GenExosome Technologies, Inc. In addition, we provide medical related consulting services in advanced areas of immunotherapy and second opinion/referral services through our wholly-owned subsidiary Avalon (Shanghai) Healthcare Technology Co., Ltd., or Avalon Shanghai. We also own and operate commercial real estate in New Jersey, where we are headquartered.
Further, we produce revenue by performing development services for hospitals and other customers and sales of developed products to hospitals and other customers through GenExosome Technologies Inc. (“GenExosome”) and Beijing Jieteng (GenExosome) Biotech Co., Ltd. (“Beijing GenExosome”).
On May 29, 2018, Avalon Shanghai entered into a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd., or Unicorn, pursuant to which a company named Epicon Biotech Co., Ltd. (“Epicon”) was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai. Within two years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000 (approximately $1.2 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon, and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.5 million). The board of directors of Epicon shall consist of five members with Unicorn appointing three members and Avalon Shanghai appointing two members. Epicon will be focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements. As of the date hereof, Unicorn has invested the premises of the laboratories of Nanjing Hospital of Chinese Medicine and Avalon Shanghai has contributed RMB 3,000,000 (approximately $0.4 million). Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements.
On July 18, 2018, the Company formed a wholly owned subsidiary, Avactis Biosciences, Inc., a Nevada corporation, which will be focused on accelerating commercial activities related to Chimeric Antigen Receptor (CAR)-T technologies. The subsidiary is designed to integrate and optimize our global scientific and clinical resources to further advance the use of CAR-T to treat certain cancers.
On July 30, 2018, the Company signed a Letter of Intent with Arbele Limited, a Hong Kong company (“Arbele”) for a proposed strategic partnership agreement. The purpose of the proposed transaction is to form a joint venture company, AVAR BioTherapeutics (China) Co. Ltd., to develop, manufacture, and commercializing CAR-T immunotherapy for treating cancer patients in China, utilizing intellectual property from Arbele and the clinical platform of the LuDaopei Medical Group in China. The Company paid a $100,000 fee to Arbele for a five-month exclusive right to complete the definitive agreements for the transaction. On October 23, 2018, Avactis Biosciences, Inc. (“Avactis”), a wholly-owned subsidiary of the Company, and Arbele agreed to the establishment of AVAR BioTherapeutics (China) Co. Ltd. (“AVAR”), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture Agreement (the “AVAR Agreement”), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy in China. Avactis is required to contribute USD $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis’ cash reserves. Within 30 days, Arbele shall make contribution of USD $6.66 million in the form of entering into a License Agreement with AVAR granting AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed upon Avactis and AVAR and services.
As of May 2019, Avactis has paid $600,000 to Arbele as research and development fee, AVAR is in process of being established and the License Agreement has not been finalized.
AVAR’s Board of Directors shall consist of three directors, of which two (2) directors shall be appointed by Avactis who shall initially be David Jin, M.D., Ph.D and one other director to be determined by Avactis and agreed to by Arbele. One director shall be appointed by Arbele who shall initially be John Luk, Dr. Med.Sc., EMBA.
On August 6, 2018, the Company entered into a strategic partnership agreement with Weill Cornell’s cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering headed by Dr. Yen-Michael Hsu. This strategic partnership aims to co-develop bio-production and standardization procedures in procurement, storage, processing, clinical study protocols, and bio-banking for Chimeric Antigen Receptor (CAR)-T therapy, in accordance with the Foundation of Accreditation for Cellular Therapy (FACT) and American Association of Blood Banks (AABB) standards. This partnership also includes a CAR-T education program to support and foster collaborative research and training programs for scientists and clinicians between Weill Cornell and Hebei Yanda LuDaopei Hospital, which is our main affiliated clinical facility as well as the world’s single largest medical institution in CAR-T therapy.
The value of the Renminbi (“RMB”), the main currency used in China, fluctuates and is affected by, among other things, changes in China’s political and economic conditions. The conversion of RMB into foreign currencies such as the U.S. dollar have generally been based on rates set by the People’s Bank of China, which are set daily based on the previous day’s interbank foreign exchange market rates and current exchange rates on the world financial markets.
Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to the allowance for doubtful accounts, reserve for obsolete inventory, the useful life of property and equipment and investment in real estate and intangible assets, assumptions used in assessing impairment of long-term assets, valuation of deferred tax assets and the associated valuation allowances, and valuation of stock-based compensation.
We base our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the consolidated financial statements.
Effective January 1, 2018, we began recognizing revenue under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. The impact of adopting the new revenue standard was not material to our consolidated financial statements and there was no adjustment to beginning accumulated deficit on January 1, 2018. The core principle of this new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:
The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct).
The entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract).
● Service fees under consulting agreements with related parties to provide medical related consulting services to our clients. We are paid for our services by our clients pursuant to the terms of the written consulting agreements. Each contract calls for a fixed payment.
● Service fees under agreements to perform development services for hospitals and other customers. We do not perform contracts that are contingent upon successful results.
● We recognize rental revenue from our commercial leases on a straight-line basis over the life of the lease including rent holidays, if any. Straight-line rent receivable consists of the difference between the tenants’ rents calculated on a straight-line basis from the date of lease commencement over the remaining terms of the related leases and the tenants’ actual rents due under the lease agreements and is included in tenants receivable in the accompanying consolidated balance sheets. Revenues associated with operating expense recoveries are recognized in the period in which the expenses are incurred.
● We recognize revenue by providing medical related consulting services under written service contracts with our customers. Revenue related to our service offerings is recognized as the services are performed.
We do not offer promotional payments, customer coupons, rebates or other cash redemption offers to our customers.
The company has not provided an Income Tax Provision (China, nor the United States) for the first quarter of 2019 due to loses being reported for both jurisdictions.
We are governed by the income tax laws of China and the United States. Income taxes are accounted for pursuant to ASC 740 “Accounting for Income Taxes,” which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. The charge for taxes is based on the results for the period as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.
Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is recognized over the period of services or the vesting period, whichever is applicable. Until the measurement date is reached, the total amount of compensation expense remains uncertain. Our compensation expense for unvested options to non-employees is re-measured at each balance sheet date and is being amortized over the vesting period of the options.
As of March 31, 2019, Dr. Yu Zhou, director and co- chief executive officer of GenExosome, who owned 40% of the equity interests of GenExosome, which is not under our control.
For details of applicable new accounting standards, please, refer to Recent Accounting Pronouncements in Note 3 of our consolidated financial statements accompanying this report.
For the three months ended March 31, 2019, we had real property rental revenue of $266,626, as compared to $296,623 for the three months ended March 31, 2018, a decrease of $29,997, or 10.1%, which was primarily attributable to the loss of a tenant in December 2018.
For the three months ended March 31, 2019, we had medical related consulting services revenue from related party of $14,260. We did not have any medical related consulting revenue during the three months ended March 31, 2018.
For the three months ended March 31, 2019, we had revenue from contract services through performing development services for hospitals and other customers and sales of developed products to hospitals and other customers of $3,278, as compared to $11,290 for the three months ended March 31, 2018, a decrease of $8,012, or 71.0%, which was primarily attributable to business fluctuation period over period. We expect that our revenue from contract services through performing development services for hospitals and other customers and sales of developed products to hospitals and other customers will have a modest increase in the near future.
For the three months ended March 31, 2019, our real property operating expenses amounted to $230,759, as compared to $210,274 for the three months ended March 31, 2018, an increase of $20,485, or 9.7%. The increase was mainly due to an increase in real property management fee of approximately $15,000 and an increase in depreciation from building improvement of approximately $8,000, offset by a decrease in other miscellaneous items of approximately $3,000.
Costs of medical related consulting services include the cost of internal labor and related benefits, travel expenses related to medical related consulting services, subcontractor costs, other related consulting costs, and other overhead costs. Subcontractor costs were costs related to medical related consulting services incurred by our subcontractor, such as medical professional’s compensation and travel costs.
For the three months ended March 31, 2019, costs of medical related consulting services amounted to $13,091.
Costs of development services and sales of developed products include inventory costs, materials and supplies costs, internal labor and related benefits, depreciation, other overhead costs and shipping and handling costs incurred.
For the three months ended March 31, 2019, costs of development services for hospitals and other customers and sales of developed products to hospitals and other customers amounted to $30,307, as compared to $16,520 for the three months ended March 31, 2018, an increase of $13,787, or 83.5%. The increase was mainly due to (i) the increase in depreciation related to our newly purchased manufacturing equipment which we started depreciating from the fourth quarter of 2018 and the first quarter of 2019; (ii) the slight increase in labor costs.
Our real property operating income for the three months ended March 31, 2019 was $35,867, representing a decrease of $50,482, or 58.5% as compared to $86,349 for the three months ended March 31, 2018. The decrease was mainly attributable the decrease in rental revenue resulting from the loss of a tenant and the increase in real property operating expenses as described above.
Gross Profit from Medical Related Consulting Services and Gross Margin
Gross profit from medical related consulting services for the three months ended March 31, 2019 was $1,169, with a gross margin of 8.2%.
Gross loss from Development Services and Sales of Developed Products and Gross Margin
Our gross loss from development services and sales of developed products for the three months ended March 31, 2019 was $27,029, as compared to $5,230 for the three months ended March 31, 2018, a change of $21,799, or 416.8%.
Gross margin decreased to (824.6)% for the three months ended March 31, 2019 from gross margin of (46.3)% for the three months ended March 31, 2018. The significant decrease in gross margin for the three months ended March 31, 2019 as compared to the corresponding 2018 period were primarily attributable to: (i) the reduced scale of operations resulting from lower revenue, which is reflected in the allocation of fixed costs, mainly consisting of depreciation and labor costs, to cost of development services and sales of developed products; (ii) the overhead costs were allocated to less production volume due to the reduced operations during the first quarter of 2019. We expect that our gross margin from this segment will continue to be negative, and we can only generate a positive gross margin if we can increase our production, thereby enabling us to operate more efficiently. Although we are selling our development services and developed products at prices which are less than our cost, we believe that, in long-term, we will be able to operate this segment profitable because we are optimistic about the long-term prospect of exosome-based diagnostic and therapeutic industry and the market for our products. However, we cannot assure you that we will be able to generate sufficient sales in this segment to operate profitably.
For the three months ended March 31, 2019 and 2018, other operating expenses consisted of the following:
Advertising expenses $ 244,600 $ -
Research and development 152,460 -
Amortization 81,893 81,893
Travel and entertainment 187,436 57,948
Other general and administrative 240,550 145,411
$ 4,475,320 $ 1,395,838
● For the three months ended March 31, 2019, we incurred advertising expenses of $244,600 to publicize and enhance our image. We did not incur any advertising expenses in the three months ended March 31, 2018.
● For the three months ended March 31, 2019, compensation and related benefits increased by $1,561,341, or 289.8%, as compared to the three months ended March 31, 2018. The significant increase was primarily attributable to an increase in stock-based compensation of approximately $1,323,000 which reflected the value of options granted and vested to our management in the first quarter of 2019, and an increase in salaries and related benefits of approximately $239,000 due to an increase in salary for our three key officers of approximately $131,000 and an increase in cash compensation for our directors of approximately $108,000.
● Professional fees primarily consisted of accounting fees, audit fees, legal service fees, consulting fees, investor relations service charges and other fees incurred for service related to being a public company. For the three months ended March 31, 2019, professional fees increased by $896,454, or 156.8%, as compared to the three months ended March 31, 2018. The increase was mainly attributable to an increase in consulting fees of approximately $843,000 due to the increase in use of consulting services providers and an increase in other miscellaneous items of approximately $53,000 reflecting our business expansion.
● For the three months ended March 31, 2019, research and development expenses increased by $152,460, or 100.0%, as compared to the three months ended March 31, 2018. We spent $152,460 in research and development activities related to the development of proprietary diagnostic and therapeutic products leveraging exosome technology and optimization of Exosome Isolation Systems in the first quarter of 2019. We did not incur any research and development activity in the first quarter of 2018.
● Amortization expense from intangible assets remained materially consistent with prior year comparable period.
● For the three months ended March 31, 2019, travel and entertainment expense increased by $129,488, or 223.5%, as compared to the three months ended March 31, 2018. The increase was mainly due to increased business travel activities incurred and increased entertainment expenditure in order to enhance our visibility in the first quarter of 2019.
● Other general and administrative expenses mainly consisted of academic sponsorship, Directors and Officers Insurance, and other miscellaneous items. For the three months ended March 31, 2019, other general and administrative expenses increased by $95,139, or 65.4%, as compared to the three months ended March 31, 2018. The increase was primarily due to an increase in academic sponsorship incurred of approximately $30,000, an increase in Directors and Officers Insurance of approximately $34,000, and an increase in other miscellaneous items of approximately $31,000 resulting from our business expansion.
As a result of the foregoing, for the three months ended March 31, 2019, loss from operations amounted to $4,465,313, as compared to $1,314,719 for the three months ended March 31, 2018, a change of $3,150,594, or 239.6%.
Other income (expense) mainly includes interest expense and loss from equity-method investment.
Other expense, net, totaled $39,616 for the three months ended March 31, 2019, as compared to $236,250 for the three months ended March 31, 2018, a change of $196,634, which was primarily attributable to a decrease in interest expense of approximately $209,000, offset by an increase in loss from equity-method investment of approximately $13,000.
We did not have any income taxes expense for the three months ended March 31, 2019 and 2018 since we incurred losses in the periods.
As a result of the factors described above, our net loss was $4,504,929 for the three months ended March 31, 2019, as compared to $1,550,969 for the three months ended March 31, 2018, a change of $2,953,960 or 190.5%.
Net Loss Attributable to Avalon GloboCare Corp. Common Shareholders
The net loss attributable to Avalon GloboCare Corp. common shareholders was $4,405,816 or $(0.06) per share (basic and diluted) for the three months ended March 31, 2019, as compared with $1,481,579, or $(0.02) per share (basic and diluted) for the three months ended March 31, 2018, a change of $2,924,237 or 197.4%.
Our reporting currency is the U.S. dollar. The functional currency of our parent company, AHS, Avalon (BVI) Ltd. (dormant, is in process of being dissolved), Avalon RT 9, GenExosome, and Avactis is the U.S. dollar and the functional currency of Avalon Shanghai and Beijing GenExosome, is the Chinese Renminbi (“RMB”). The financial statements of our subsidiaries whose functional currency is the RMB are translated to U.S. dollars using period end rates of exchange for assets and liabilities, average rate of exchange for revenue, costs, and expenses and cash flows, and at historical exchange rates for equity. Net gains and losses resulting from foreign exchange transactions are included in the results of operations. As a result of foreign currency translations, which are a non-cash adjustment, we reported a foreign currency translation gain of $43,482 and $52,838 for the three months ended March 31, 2019 and 2018, respectively. This non-cash gain had the effect of decreasing our reported comprehensive loss.
As a result of our foreign currency translation adjustment, we had comprehensive loss of $4,461,447 and $1,498,131 for the three months ended March 31, 2019 and 2018, respectively.
Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations and otherwise operate on an ongoing basis. At March 31, 2019 and December 31, 2018, we had cash balance of approximately $1,769,000 and $2,252,000, respectively. These funds are kept in financial institutions located as follows:
The current PRC Enterprise Income Tax (“EIT”) Law and its implementing rules generally provide that a 10% withholding tax applies to China-sourced income derived by non-resident enterprises for PRC enterprise income tax purposes unless the jurisdiction of incorporation of such enterprises’ shareholder has a tax treaty with China that provides for a different withholding arrangement.
The following table sets forth a summary of changes in our working capital from December 31, 2018 to March 31, 2019:
December 31, 2018 to
2019 December 31, 2018 Change Percentage Change
Total current assets $ 2,923,402 $ 3,625,432 $ (702,030 ) (19.4 )%
Total current liabilities 2,663,753 1,141,720 1,522,033 133.3 %
Working capital $ 259,649 $ 2,483,712 $ (2,224,063 ) (89.5 )%
Our working capital decreased by $2,224,063 to working capital of $259,649 at March 31, 2019 from working capital of $2,483,712 at December 31, 2018. The decrease in working capital was primarily attributable an increase in a loan payable – current portion of approximately $1,000,000, a decrease in cash of approximately $483,000, a decrease in prepaid expenses – related parties of approximately $34,000, a decrease in prepaid expenses and other current assets of approximately $197,000, an increase in accounts payable of approximately $34,000, an increase in accrued liabilities and other payables of approximately $432,000, an increase in accrued liabilities and other payables – related parties of approximately $34,000, an increase in interest payable of approximately $25,000, and an increase in VAT and other taxes payable of approximately $21,000, offset by a decrease in advance from customer – related party of approximately $15,000 and a decrease in deferred rental income of approximately $11,000.
Cash Flows for the Three Months Ended March 31, 2019 Compared to the Three Months Ended March 31, 2018
The following summarizes the key components of our cash flows for the three months ended March 31, 2019 and 2018:
Net cash used in operating activities $ (1,422,311 ) $ (416,234 )
Net decrease in cash $ (482,996 ) $ (901,377 )
Net cash flow used in operating activities for the three months ended March 31, 2019 was $1,422,311, which primarily reflected our net loss of approximately $4,505,000, and the changes in operating assets and liabilities, primarily consisting of a decrease in advance from customer – related party of approximately $15,000, and a decrease in deferred rental income of approximately $11,000, offset by a decrease in prepaid expenses – related parties of approximately $35,000, a decrease in prepaid expenses and other current assets of approximately $198,000, an increase in accounts payable of approximately $34,000, an increase in accrued liabilities and other payables of approximately $347,000, an increase in accrued liabilities and other payables – related parties of approximately $34,000, an increase in interest payable of approximately $25,000, and an increase in VAT and other taxes payable of approximately $21,000, and the add-back of non-cash items consisting of depreciation and amortization of approximately $139,000, stock-based compensation expense of approximately $2,273,000, and loss on equity method investment of approximately $13,000.
Net cash flow used in operating activities for the three months ended March 31, 2018 was $416,234, which primarily reflected our net loss of approximately $1,551,000, and the changes in operating assets and liabilities, primarily consisting of a decrease in accrued liabilities and other payables – related parties of approximately $14,000, and a decrease in tenants’ security deposit of approximately $19,000, offset by a decrease in prepaid expenses and other current assets of approximately $76,000, an increase in accrued liabilities and other payables of approximately $178,000, an increase in interest payable of approximately $237,000, an increase in VAT and other taxes payable of approximately $31,000, and the add-back of non-cash items consisting of depreciation and amortization expense of approximately $123,000, and stock-based compensation and service fees of approximately $526,000.
● the development and commercialization of exosome products;
● an increase in professional staff and services including increased costs of being a public company; and
● an increase in public relations and/or sales promotions for existing and/or new brands as we expand within existing markets or enter new markets.